Risk Factors for Resistance to β-Lactam/β-Lactamase Inhibitors and Ertapenem in Bacteroides Bacteremia

Antimicrob Agents Chemother. 2015 Aug;59(8):5049-51. doi: 10.1128/AAC.00046-15. Epub 2015 Jun 1.

Abstract

The objective of this study was to determine risk factors for the development of resistance to β-lactams/β-lactamase inhibitors (βL/βLIs) and ertapenem among Bacteroides species bacteremia. We conducted a retrospective case-control study of 101 adult patients with Bacteroides species bacteremia at a 1,051-bed tertiary care medical center. The duration of exposure to βL/βLIs (odds ratio [OR], 1.25; 95% confidence interval [CI], 1.08 to 2.31) was the only independent risk factor for resistance.

MeSH terms

  • Adult
  • Anti-Bacterial Agents / therapeutic use
  • Bacteremia / drug therapy
  • Bacteroides / classification
  • Bacteroides / drug effects*
  • Bacteroides Infections / drug therapy*
  • Bacteroides Infections / epidemiology
  • Case-Control Studies
  • Drug Resistance, Bacterial
  • Drug Therapy, Combination
  • Ertapenem
  • Humans
  • Microbial Sensitivity Tests
  • Retrospective Studies
  • Risk Factors
  • Tertiary Care Centers
  • beta-Lactamase Inhibitors / therapeutic use*
  • beta-Lactams / therapeutic use*

Substances

  • Anti-Bacterial Agents
  • beta-Lactamase Inhibitors
  • beta-Lactams
  • Ertapenem